TOP > 外国特許検索 > MEDICINE COMPRISING MODULATOR OF ACTIVITY OF CD300a-EXPRESSING CELL ASSOCIATED WITH ALLERGIC DISEASE, CD300a GENE KNOCK-OUT MOUSE, AND USE OF MODULATOR OF ACTIVITY OF CD300a-EXPRESSING CELL

MEDICINE COMPRISING MODULATOR OF ACTIVITY OF CD300a-EXPRESSING CELL ASSOCIATED WITH ALLERGIC DISEASE, CD300a GENE KNOCK-OUT MOUSE, AND USE OF MODULATOR OF ACTIVITY OF CD300a-EXPRESSING CELL

外国特許コード F150008173
掲載日 2015年3月19日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2013JP079890
国際公開番号 WO 2014073529
国際出願日 平成25年11月5日(2013.11.5)
国際公開日 平成26年5月15日(2014.5.15)
優先権データ
  • 特願2012-245816 (2012.11.7) JP
発明の名称 (英語) MEDICINE COMPRISING MODULATOR OF ACTIVITY OF CD300a-EXPRESSING CELL ASSOCIATED WITH ALLERGIC DISEASE, CD300a GENE KNOCK-OUT MOUSE, AND USE OF MODULATOR OF ACTIVITY OF CD300a-EXPRESSING CELL
発明の概要(英語) Provided are: a medicine for an allergic disease (e.g., atopic dermatitis, asthma); and a tool useful for the analysis of a clinical condition of an allergic disease. A medicine, which contains a substance capable of inhibiting the binding between CD300a and phosphatidyl serine and comprises, as an active ingredient, an activity modulator that can inhibit the inhibitory signal transduction of a myeloid cell capable of expressing CD300a, can be used for treating or preventing an allergic disease. A CD300a gene knock-out mouse can be used for analyzing a clinical condition of an allergic disease or screening for a candidate substance that can act as an active ingredient for a therapeutic or prophylactic agent for the allergic disease, as a model mouse that rarely develops the allergic disease when a substance capable of inducing the allergic disease is administered to the mouse.
従来技術、競合技術の概要(英語) BACKGROUND ART
Host (human or animal body) the pathogen (bacteria, virus, parasite or the like) invasion, endogenous disease-body and the materials are produced, a site of pathogenic infestation or disease-material generated at the site of arterioles after temporarily contraction, expansion, to reach a hyperemia, a site of pathogenic infestation or disease-site material generated locally becomes slow blood flow such as inflammatory reaction may occur.
Then, leukocytes stuck to the vessel wall, immune system is configured to output various is released from cells by the action of, an ameba-like movement through the vessel wall to migrate. As , histamine, serotonin, lymphokines and the like are known. Histamine or serotonin production, mast cells release, plays a central role in inflammatory response is one of the lymphocytes. In addition, in the same manner as mast cells such as macrophages also produce TNF , release.
By the inflammatory response, such as leukocyte migration and is attracted to the pathogen, a pathogen antigen-antibody reaction with humoral immunity and cytotoxic T cells and so involved by cellular immunity, pathogen (clearance) and cleared from the body, is prevented from being spread. In this way, based on the acquired immune response and inflammatory response, in order to maintain homeostasis of the living body is of essential importance.
On the other hand, the inflammatory response, as described above and bio-defence, redness, heat, swelling, pain, dysfunction problems such as the signs, symptoms may indicate. As such a condition, specifically, allergic diseases, and various acute or chronic inflammation. In addition, immunological tolerance is not applied, self-immune occurs even in case the autoimmune disease, tissue injury occurs in the inflammatory response.
That is, preventing a disease associated with the inflammatory response, inflammatory response and trigger various pathogens killed by the antibiotic (antimicrobial agent) as such, to improve the immune function in vivo drug administration, before the excess inflammatory response enhancement, it is important to remove the pathogen.
On the other hand, improvement in a disease associated with inflammatory response, the treatment of, for example, inhibit the release of the such as, over-activated agents that reduce the immune function after administration of the (anti-inflammatory agent), is the result of inflammation can be known.
For example, Patent Document 1 is, as immune activity, various immune system cells as an antigen presenting cell activating function activation of dendritic cells is disclosed, specifically, isoleucine, leucine and valine 1 of at least one selected from a branched chain amino acid characterized in that the active ingredient according to the present invention.
Patent Document 2 is, as anti-inflammatory agents, peptides and pharmacologically SPARC (Secreted prоtein which is acidic and rich in cystein) carrier agent is disclosed.
However, responsible for the innate immune system cells (myeloid) system is on the cell membrane, referred to as a receptor molecule MAIR(Myeloid Associated Ig like Receptors) group is known to be expressed (non-patent document 1). Among these, also known as CD300a (other 'LMIR1', 'CLM-8' and may be called a) MAIR-I is, macrophages, mast cells, granulocytes (neutrophils), and expressed by dendritic cells, via a sequence ITIM(Immunoreceptor tyrosine-based inhibitory motif) of intracellular region associated with the phosphatase, inhibitory signals that are known to be inhibitory receptor (non-patent document 2) are. However, the ligand for a receptor is unknown, there has been a so-called orphan receptors.
Atopic dermatitis is, allergenic material enters the body (antigen), secreted from activated immune cells (interleukin 4, 13) material is made is a fibroblast stimulation, the surface of the skin keratinocytes' integrin ' another protein can be bonded to the cause can cause inflammation.
New by the binding of the integrin to a fibroblast proinflammatory agent is produced, even without the antigen to improved and continued and chronic. Experiment using mice, by an inhibitor of binding of the integrin to a fibroblast inhibition, does not take place any atopic dermatitis is shown (non-patent document 3).
Atopic dermatitis but it became clear that the main etiology, further elucidation of the disease state of atopic dermatitis and other inflammatory disease and analyzing the association, can be used in combination with an inhibitor of the medicament for atopic dermatitis and the like has been desired.
On the other hand, bronchial asthma and allergic reactions (Bronchial Asthma) or a bacterium, virus infection is a chronic inflammation of the bronchi which gave rise to the embodiment of the enhancement of airway hyperresponsiveness, airway constriction and is thus reversible, attack such as wheezing, coughing and interfering with the symptoms of a respiratory disease. Also, bronchial asthma, airway hyperresponsiveness, allergic constitution, it is assumed that a combination of environment occurs. To dictate the notification, apnea, recurrent symptoms such as chest tightness and cough in the form of expression, particularly night or early morning appears.
Many cells and cell components, particularly mast cells, eosinophils, T lymphocytes, macrophages, neutrophils and epithelial cells, plays a role in airway inflammation. Inflammation, plasma exudate, edema, smooth muscle hypertrophy, mucus and epithelial changes infarction (mucus plugging) the filler is associated with. In addition, inflammation may be, is present for the variety of stimuli causing an increase in the associated bronchial hyperresponsiveness.
Airway inflammation, airway smooth muscle atrophy, leading to rupture of small blood vessels and bronchial hyperresponsiveness. Of the airway reactivity is high and reacts, symptoms are more heavy, and continuously, the size of the lung function of the variation of greater than during the day. Bronchial airway inflammation is associated with the reactivity of the mechanism is unknown, and a useful tool in the elucidation of the pathophysiology of asthma, medical supplies and the like has been desired.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • UNIVERSITY OF TSUKUBA
  • 発明者(英語)
  • SHIBUYA, Akira
  • ODA, Chigusa
  • KANKANAM GAMAGE, Udayanga Sanath
  • MIKI, Haruka
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG
この特許について質問等ある場合は、電子メールによりご連絡ください。

PAGE TOP

close
close
close
close
close
close